临床数据调查确定MARK3作为割抵抗性前列腺癌的致癌驱动因素
Rajnikant Raut1, Devesh Srivastava1, Vinayak Nayak1
1Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502285, India.
Biochemistry and biophysics reports
|April 18, 2025
概括
微管类亲和调节激酶3 (MARK3) 是割耐性前列腺癌 (CRPC) 的新型驱动因素. 抑制MARK3可以减少癌细胞的生长和迁移,为CRPC患者提供了一个有前途的新治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 抗割前列腺癌 (CRPC) 是一种具有有限治疗选择的侵袭性恶性瘤.
- 治疗耐药性是治疗晚期前列腺癌的一个主要挑战.
- 激酶和酸酶失调与CRPC进展有关.
研究的目的:
- 通过全面的转录基因分析,通过CRPC识别新的治疗点.
- 为了研究微管亲和调节激酶3 (MARK3) 在CRPC中的作用.
- 评估CRPC中MARK3抑制的治疗潜力.
主要方法:
- 从癌症基因组图谱中对359个正常和CRPC患者样本进行转录组分析.
- 基于差异表达,生存数据和对癌细胞的功能影响的候选基因的in-silico识别和验证.
- 在前列腺癌细胞系中使用PCC0208017进行MARK3的药理抑制.
- RNA测序以分析MARK3抑制剂介导的基因表达变化.
主要成果:
- 在CRPC患者中,MARK3被确定为显著上调的激酶,与生存率低下和癌细胞适应性降低有关.
- 药理上抑制MARK3降低了前列腺癌细胞活力,迁移,并诱导G1细胞周期停止.
- 抑制MARK3调节的基因参与了雄激素反应,上皮-介质细胞过渡,mTOR和myc信号通路.
结论:
- 马克3是CRPC进展的一个新型驱动器.
- 马克3代表了一种有前途的治疗割抵抗性前列腺癌的目标.
- 向MARK3可能为克服晚期前列腺癌治疗阻力提供了一种新策略.
相关概念视频
02:23Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K